SVA-PEG Hemoglobin Conjugates for Reduced Vasoconstriction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemoglobin-based oxygen carriers (HBOCs) face challenges due to vasoconstriction caused by nitric oxide scavenging, leading to hypertension, and existing conjugation methods result in heterogeneous products with high molar excess reactants, increasing costs and product heterogeneity.
Innovation Solution
The development of polyalkylene oxide (PAO) hemoglobin conjugates using succinimidyl-valerate activated PEG (SVA-PEG) that binds to hemoglobin under specific conditions, forming a stable and homogeneous conjugate with enhanced stability and reduced vasoconstrictive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If hemoglobin is used as an oxygen carrier, then oxygen delivery capability is improved, but vasoconstriction occurs due to nitric oxide scavenging
Solution Approach 1:
The patent removes the harmful heme group from the hemoglobin molecule, creating a hemoglobin variant that lacks the nitric oxide scavenging capability while retaining oxygen binding functionality. This extraction of the problematic component resolves the vasoconstriction issue while preserving the beneficial oxygen delivery function.
Solution Approach 2:
The patent modifies the molecular weight parameter of hemoglobin through conjugation with polyalkylene oxide polymers, changing it from the native ~64,000 Da to significantly higher values. This parameter change affects the pharmacokinetic properties, extending circulation half-life and reducing renal clearance, thereby improving overall therapeutic performance while mitigating vasoconstrictive effects.
2Duration of action of stationary object
If conventional PEG conjugation methods are used to modify hemoglobin, then circulation half-life is extended, but product heterogeneity increases and high molar excess reactants are required
Solution Approach 1:
The patent changes the chemical parameters of the conjugation reaction by using activated esters instead of conventional PEG reagents, conducting the reaction at physiological pH (7.4) and temperature (4°C), and using stoichiometric or near-stoichiometric amounts of reagents. These parameter changes enable controlled, homogeneous conjugation without requiring high molar excess reactants, thereby improving manufacturing precision while achieving the desired circulation half-life extension.
3Stability of the object's composition
If hemoglobin is cross-linked to prevent dissociation, then stability is improved, but oxygen affinity may be altered
Solution Approach 1:
The patent applies cross-linking at specific local sites within the hemoglobin tetramer structure, using site-specific reagents that target particular amino acid residues. This localized approach to cross-linking stabilizes the tetramer configuration without globally altering the heme environment, thereby maintaining normal oxygen affinity while achieving the desired structural stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PAO hemoglobin conjugates exhibit improved stability, homogeneity, and reduced vasoconstriction, with a P50 ranging from 2 to 10 mmHg, allowing for effective oxygen delivery and nitric oxide conversion in the microvasculature, while minimizing unwanted side products and reaction time.
Implementation Method 1
succinimidyl-valerate activated PEG (SVA-PEG) that binds to hemoglobin under specific conditions, forming a stable and homogeneous conjugate
Implementation Method 2
allowing for effective oxygen delivery and nitric oxide conversion in the microvasculature
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates generally to polyethylene glycol (PEG) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of the hemoglobin.